Venture Houston 2018
Skip Content


8 November 2017

ADCendo secures Copenhagen licence

ADCendo will develop a single oncology therapy combining antibodies with cytotoxic drugs used during chemotherapy.

Author: Callum Cyrus, reporter

ADCendo, a Denmark-based cancer treatment developer has signed a licensing agreement with University of Copenhagen and local government administration Capital Region of Denmark for potential treatments for bone, connective tissue and brain cancers.

Founded in July 2017, ADCendo hopes to develop antibody-drug conjugates – a compound connecting immune system antibodies, which target bacteria and viruses, with the cytotoxic compounds often used to kill cells during chemotherapy.

The therapy would work via the uParap receptor, which plays a role in wearing down basement membrane, a barrier stopping malignant cells from entering deeper tissues.

ADCendo is based on research led by Niels Behrendt at the Finsen Laboratory in the university teaching hospital Rigshospitalet, with Christoffer Nielsen and Lars Engelholm.

The three researchers co-founded the company with Henrik Stage, former chief executive and chief financial officer of biopharmaceutical firm Santaris Pharma, acquired by healthcare company Roche in 2014.

The research was partially funded through a pre-seed grant from Novo Seeds, the early-stage investment arm of pharmaceutical firm Novo.

University of Copenhagen and Capital Region of Denmark are eligible to collect milestone payments and royalties under the licence agreement.

Niels Skjærbæk, senior executive adviser at Research & Innovation, the university’s tech transfer office, said: “A promising spinout biotech company is always a significant achievement.

“The ADCendo founders have been very focused and displayed great determination through this process, we are therefore all very excited about this new cancer biotech company, and we will follow the drug development challenges with great interest.”

Copyright Mawsonia Limited 2010. Please don´t cut articles from or the PDF and redistribute by email or post to the web without written permission.

  • Linkedin
  • Mail
  • Rssfeed